Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Patrice Benner"'
Autor:
James T. Peterson, Helen L. Stacey, John E. MacNair, Jianing Li, Jonathan S. Hartzel, Tina M. Sterling, Patrice Benner, Gretchen M. Tamms, Luwy K. Musey
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 3, Pp 540-548 (2019)
Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 wa
Externí odkaz:
https://doaj.org/article/3b328c23fcc848fa93e938fb462d2280
Autor:
Helen L. Stacey, Jeffrey Rosen, James T. Peterson, Angela Williams-Diaz, Vanita Gakhar, Tina M. Sterling, Camilo J. Acosta, Katrina M. Nolan, Jianing Li, Alison Pedley, Patrice Benner, Chitrananda Abeygunawardana, Michael Kosinski, William J. Smith, Hari Pujar, Luwy K. Musey
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 3, Pp 530-539 (2019)
Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugat
Externí odkaz:
https://doaj.org/article/6ec605d19b074bb1968a1f0423976419
Autor:
William J. Smith, Tina M. Sterling, Camilo J. Acosta, Kosinski Michael J, Chitrananda Abeygunawardana, Helen L. Stacey, Patrice Benner, Luwy Musey, Angela Williams-Diaz, Alison Pedley, Jeffrey M. Rosen, James T. Peterson, Jianing Li, Katrina M. Nolan, Hari Pujar, Vanita Gakhar
Publikováno v:
Human Vaccines & Immunotherapeutics. 15:530-539
Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugat
Autor:
S. Grayson, Luwy Musey, Jianing Li, Chitrananda Abeygunawardana, David H. Hurley, Patrice Benner, Jonathan Hartzel, Hari Pujar, Richard E. Rupp, Michael A. Winters, Richard D. McFetridge, Katrina M. Nolan
Publikováno v:
Human vaccinesimmunotherapeutics. 15(3)
Background: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037
Autor:
James T. Peterson, Jonathan Hartzel, Helen L. Stacey, Jianing Li, Tina M. Sterling, John E. Macnair, Patrice Benner, Luwy Musey, Gretchen M. Tamms
Publikováno v:
Human vaccinesimmunotherapeutics. 15(3)
Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 wa
Autor:
Tina M. Sterling, Alison Pedley, Helen L. Stacey, Jon E. Stek, Chitrananda Abeygunawardana, Michael A. Winters, Kosinski Michael J, Ulrike K. Buchwald, Katrina M. Nolan, Patrice Benner, Luwy Musey, Melanie Bruch, Gretchen M. Tamms, Katie Julien, Jianing Li, James Peterson
Publikováno v:
Open Forum Infectious Diseases
Background Safety and immunogenicity of a new formulation of PCV-15 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F*, 23F, 33F*) was evaluated in adults ≥65 years of age previously vaccinated with PPV23. Methods Study subjects who received PPV2